TY - JOUR
T1 - Pharmacological treatment options for hypertrophic cardiomyopathy
T2 - high time for evidence.
AU - Spoladore, Roberto
AU - Maron, Martin S.
AU - D'Amato, Rossella
AU - Camici, Paolo G.
AU - Olivotto, Iacopo
PY - 2012/7
Y1 - 2012/7
N2 - Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, affecting over one million individuals in Europe. Hypertrophic cardiomyopathy patients often require pharmacological intervention for control of symptoms, dynamic left ventricular outflow obstruction, supraventricular and ventricular arrhythmias, and microvascular ischaemia. Current treatment strategies in HCM are predicated on the empirical use of long-standing drugs, such as beta-adrenergic and calcium blockers, although with little evidence supporting their clinical benefit in this disease. In the six decades since the original description of the disease,
AB - Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, affecting over one million individuals in Europe. Hypertrophic cardiomyopathy patients often require pharmacological intervention for control of symptoms, dynamic left ventricular outflow obstruction, supraventricular and ventricular arrhythmias, and microvascular ischaemia. Current treatment strategies in HCM are predicated on the empirical use of long-standing drugs, such as beta-adrenergic and calcium blockers, although with little evidence supporting their clinical benefit in this disease. In the six decades since the original description of the disease,
UR - http://www.scopus.com/inward/record.url?scp=84867151300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867151300&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehs150
DO - 10.1093/eurheartj/ehs150
M3 - Article
C2 - 22719025
AN - SCOPUS:84867151300
VL - 33
SP - 1724
EP - 1733
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 14
ER -